Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

Short summary

Combining nivolumab (PD-1 inhibitor) and ipilimumab (CTLA-4 inhibitor) significantly improved progression-free survival (PFS) in untreated metastatic melanoma patients compared to ipilimumab alone (11.5 vs. 2.9 months) and nivolumab alone (11.5 vs. 6.9 months). The combination was particularly effective in patients with PD-L1-negative tumors.

AI-generated from the title and abstract; the full text is not read.